Roth Capital Has Negative Outlook of Enovis FY2025 Earnings

Enovis Co. (NYSE:ENOV) – Analysts at Roth Capital decreased their FY2025 EPS estimates for Enovis in a research note issued on Thursday, February 27th. Roth Capital analyst J. Wittes now expects that the company will post earnings of $3.24 per share for the year, down from their previous estimate of $3.31. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ FY2026 earnings at $3.74 EPS.

Separately, Needham & Company LLC dropped their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday.

Enovis Stock Performance

ENOV opened at $38.67 on Friday. The firm has a market cap of $2.20 billion, a P/E ratio of -17.66 and a beta of 1.94. Enovis has a 1-year low of $37.60 and a 1-year high of $63.96. The company has a 50 day simple moving average of $44.81 and a two-hundred day simple moving average of $44.29. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to analyst estimates of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%.

Hedge Funds Weigh In On Enovis

Hedge funds have recently modified their holdings of the company. River Road Asset Management LLC purchased a new position in shares of Enovis in the third quarter worth $51,341,000. Hood River Capital Management LLC purchased a new position in shares of Enovis in the fourth quarter worth $29,024,000. Paradigm Capital Management Inc. NY lifted its holdings in shares of Enovis by 2,566.0% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 533,200 shares of the company’s stock worth $23,397,000 after buying an additional 513,200 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Enovis in the fourth quarter worth $16,407,000. Finally, Royce & Associates LP lifted its holdings in shares of Enovis by 16.8% in the third quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock worth $103,479,000 after buying an additional 346,317 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.